Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics bolsters its team

Professor Mark Dawson and Dr Paul Leeson join its scientific advisory board

UK-based drug discovery group Storm Therapeutics has strengthened its scientific advisory board with the addition of Professor Mark Dawson.

As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.

Dr Paul Leeson also joins the University of Cambridge spin-out, following 35 years’ experience of drug discovery and development in senior roles in pharmaceutical companies including GlaxoSmithKline, Merck Sharp and Dohme and AstraZeneca.

Keith Blundy, chief executive officer of Storm Therapeutics, said: “Mark’s expertise in epigenetics research will be invaluable as we advance selected targets into drug discovery, along with Paul’s long standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of important biology.”

3rd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics